Company Futura Medical plc

Equities

FUM

GB0033278473

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - London S.E. Other stock markets 11:35:25 2024-04-26 am EDT			5-day change	1st Jan Change
35.45 ^GBX	+0.14%		-0.56%	+39.02%

Apr. 10	Futura Medical hails results as erectile dysfunction drug drives sales	AN
Apr. 10	Transcript : Futura Medical plc, 2023 Earnings Call, Apr 10, 2024

Futura Medical plc is a United Kingdom-based pharmaceutical company. The Company is engaged in the development and sale of pharmaceutical and healthcare products. It is focused on developing a portfolio of products based on its transdermal DermaSys technology. The DermaSys is designed to deliver clinically proven medical treatments via the skin. DermaSys platform with penetration and permeation enhancer components tailored for each product to suit the specific therapeutic indication and desired speed of onset and duration of action. Such targeted delivery offers an optimized profile in terms of dose, onset time and duration of effect. The Company's products include MED3000 and TPR100. The Company's lead product, MED3000, is a topical gel formulation treatment for erectile dysfunction (ED) through an evaporative mode of action. The Company has conducted a Phase III study using MED3000 in ED. The Company is also developing CBD100, which is a topical cannabidiol formulation.

Number of employees: 12

Managers	Title	Age	Since
James Barder CEO	Chief Executive Officer	-	01-05-31
Angela Hildreth DFI	Director of Finance/CFO	-	18-02-19
Ken James CTO	Chief Tech/Sci/R&D Officer	-	16-03-30

Members of the board	Title	Age	Since
Jeffrey Needham CHM	Chairman	68	21-10-07
Gordon Davis BRD	Director/Board Member	67	Jan. 08
James Barder CEO	Chief Executive Officer	-	01-05-31
Andrew Unitt BRD	Director/Board Member	66	21-12-31
Angela Hildreth DFI	Director of Finance/CFO	-	18-02-19
Ken James CTO	Chief Tech/Sci/R&D Officer	-	16-03-30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	301,449,451	202,323,826 ( 67.12 %)	0	67.12 %

Name	Equities	%	Valuation
Lombard Odier Asset Management (Europe) Ltd. 22.64 %	68,254,045	22.64 %	35 M p
UBS Asset Management (UK) Ltd. 11.10 %	33,456,000	11.10 %	17 M p
Janus Henderson Investors UK Ltd. 8.811 %	26,560,000	8.811 %	14 M p
T. Adams 6.687 %	20,158,686	6.687 %	10 M p
W.T. Lamb Holdings Ltd. 4.377 %	13,195,308	4.377 %	7 M p
Lombard Odier Asset Management (USA) Corp. 3.554 %	10,713,000	3.554 %	5 M p
Robin Anthony Lamb 3.183 %	9,596,588	3.183 %	5 M p
Hargreaves Lansdown Asset Management Ltd. 2.950 %	8,894,000	2.950 %	5 M p
Atlantis Investment Management Ltd. /Hong Kong/ 2.634 %	7,940,000	2.634 %	4 M p
Chelverton Asset Management Ltd. 2.405 %	7,250,000	2.405 %	4 M p

Futura Medical Plc

Surrey Technology Centre 40 Occam Road

GU2 7YG, Guildford

+44 14 8368 5670

http://www.futuramedical.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.3545 GBP

Average target price

1.263 GBP

Spread / Average Target

+256.37%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
FUTURA MEDICAL PLC	+39.02%	133M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs